BR112020021329A2 - inibidores de stat3 - Google Patents
inibidores de stat3 Download PDFInfo
- Publication number
- BR112020021329A2 BR112020021329A2 BR112020021329-2A BR112020021329A BR112020021329A2 BR 112020021329 A2 BR112020021329 A2 BR 112020021329A2 BR 112020021329 A BR112020021329 A BR 112020021329A BR 112020021329 A2 BR112020021329 A2 BR 112020021329A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- nrbrc
- compound according
- ora
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polymerisation Methods In General (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659872P | 2018-04-19 | 2018-04-19 | |
| US62/659,872 | 2018-04-19 | ||
| US201962793491P | 2019-01-17 | 2019-01-17 | |
| US62/793,491 | 2019-01-17 | ||
| PCT/US2019/028135 WO2019204614A1 (en) | 2018-04-19 | 2019-04-18 | Stat3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020021329A2 true BR112020021329A2 (pt) | 2021-04-27 |
Family
ID=68240338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020021329-2A BR112020021329A2 (pt) | 2018-04-19 | 2019-04-18 | inibidores de stat3 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11826315B2 (https=) |
| EP (2) | EP3773537B1 (https=) |
| JP (1) | JP7411315B2 (https=) |
| KR (1) | KR102792113B1 (https=) |
| CN (1) | CN112367984B (https=) |
| AU (1) | AU2019255755B2 (https=) |
| BR (1) | BR112020021329A2 (https=) |
| DK (1) | DK3773537T3 (https=) |
| ES (1) | ES2911428T3 (https=) |
| HU (1) | HUE059318T2 (https=) |
| IL (1) | IL278112B2 (https=) |
| MX (1) | MX2020011065A (https=) |
| MY (1) | MY207195A (https=) |
| PH (1) | PH12020551728A1 (https=) |
| PL (1) | PL3773537T3 (https=) |
| PT (1) | PT3773537T (https=) |
| SG (1) | SG11202010347XA (https=) |
| WO (1) | WO2019204614A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7411315B2 (ja) * | 2018-04-19 | 2024-01-11 | トゥヴァルディ セラピューティクス，インク． | Ｓｔａｔ３阻害剤 |
| CN114761405A (zh) * | 2019-11-29 | 2022-07-15 | 南京明德新药研发有限公司 | 抗hbv的1,7-萘啶类化合物 |
| JP2023504194A (ja) * | 2019-12-03 | 2023-02-01 | ベイラー カレッジ オブ メディスン | インスリン耐性における使用方法のための治療化合物 |
| JP2023520273A (ja) * | 2020-01-24 | 2023-05-17 | トゥヴァルディ セラピューティクス，インク． | 治療化合物、製剤、およびその使用 |
| CN114286684B (zh) * | 2020-07-27 | 2024-01-05 | 华中科技大学 | 与stat3相关的疾病的预防和/或治疗 |
| AR128676A1 (es) * | 2022-03-01 | 2024-06-05 | Tvardi Therapeutics Inc | Compuestos terapéuticos, formulaciones, uso y método de preparación |
| US20250170079A1 (en) * | 2022-03-04 | 2025-05-29 | Tvardi Therapeutics, Inc. | Combinations of stat-inhibitors and immune checkpoint inhibitors for the treatment and/or management of cancer |
| CA3254067A1 (en) | 2022-06-15 | 2023-12-21 | Tvardi Therapeutics, Inc. | STAT3 INHIBITOR MEDICINES |
| TW202412749A (zh) * | 2022-07-21 | 2024-04-01 | 美商特梵迪治療股份有限公司 | 治療性化合物、調配物、及其用途 |
| EP4633620A1 (en) * | 2022-12-12 | 2025-10-22 | Tvardi Therapeutics, Inc. | Stat3 inhibitors for use in the treatment of non-viral liver cancer |
| WO2025184497A1 (en) * | 2024-02-29 | 2025-09-04 | Tvardi Therapeutics, Inc. | Stat3 inhibitors for use in the treatment of cancer |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4279909A (en) | 1980-02-13 | 1981-07-21 | Fujisawa Pharmaceutical Co., Ltd. | Antiallergic method |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6492428B1 (en) | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
| US6197749B1 (en) | 1997-10-29 | 2001-03-06 | Ajinomoto Co., Inc. | Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes |
| CA2413878A1 (en) | 2000-06-20 | 2001-12-27 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| JP2005522457A (ja) | 2002-02-26 | 2005-07-28 | ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート | 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害 |
| WO2005026134A1 (en) | 2003-09-17 | 2005-03-24 | Novartis Ag | Organic compounds |
| US20050287664A1 (en) | 2004-05-27 | 2005-12-29 | Ming-Ji Fann | Cellular proliferation control factors |
| US20060148715A1 (en) | 2004-12-20 | 2006-07-06 | Baylor College Of Medicine | Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands |
| US20100035793A1 (en) | 2005-07-27 | 2010-02-11 | Cheh Peng Lim | Modulators |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| CA2636909A1 (en) | 2006-01-13 | 2007-07-26 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production with tanshinones |
| WO2007136858A2 (en) | 2006-05-19 | 2007-11-29 | H. Lee Moffitt Cancer Center & Research Institute | Small molecule inhibitors of stat3 with anti-tumor activity |
| US20090264353A1 (en) | 2007-10-19 | 2009-10-22 | Santaris Pharma A/S | Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease |
| HRP20160625T1 (hr) * | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
| WO2009038784A1 (en) | 2007-09-21 | 2009-03-26 | Amgen Inc. | Triazole fused heteroaryl compounds as p38 kinase inhibitors |
| EP2299999B1 (en) * | 2008-06-04 | 2017-08-16 | Baylor College Of Medicine | Stat3 inhibitors |
| GB2463514C (en) | 2008-09-11 | 2018-09-26 | Galapagos Nv | Imidazolidine compounds and uses therefor |
| WO2010080581A2 (en) | 2008-12-19 | 2010-07-15 | The Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Valproic acid, derivatives, analogues, and compositions including same and methods for their therapeutic use |
| US8557805B2 (en) | 2008-12-29 | 2013-10-15 | Takeda Pharmaceutical Company Limited | Fused ring compound and use thereof |
| US9891213B2 (en) | 2009-01-12 | 2018-02-13 | The Board Of Trustees Of The Leland Stanford Junior University | Granulocyte-based methods for detecting and monitoring immune system disorders |
| CA2781706A1 (en) * | 2009-11-24 | 2011-06-03 | The Ohio State University | Transcription factor inhibitors and related compositions, formulations and methods |
| FR2962649B1 (fr) | 2010-07-19 | 2025-10-24 | Conservatoire Nat Arts Et Metiers | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide |
| US20140371188A1 (en) | 2011-11-23 | 2014-12-18 | University Of Iowa Research Foundation | Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy |
| EP2708535A1 (en) | 2012-05-11 | 2014-03-19 | Les Laboratoires Servier | Agents for treating disorders involving modulation of ryanodine receptors |
| CN102766103B (zh) * | 2012-07-24 | 2014-12-10 | 齐鲁制药有限公司 | 2-硫代-4-胺基-1-萘酚衍生物、其制备方法和用途 |
| AU2014290363B2 (en) * | 2013-07-18 | 2019-02-21 | Baylor College Of Medicine | Methods and compositions for treatment of fibrosis |
| AU2014290368B2 (en) | 2013-07-18 | 2019-07-11 | Baylor College Of Medicine | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |
| US20150031714A1 (en) | 2013-07-18 | 2015-01-29 | Baylor College Of Medicine | Methods and compositions for prevention of allergic reaction |
| WO2017083719A1 (en) * | 2015-11-13 | 2017-05-18 | William Marsh Rice University | Transition metal free methods of synthesis of biaryl compounds |
| JP7411315B2 (ja) * | 2018-04-19 | 2024-01-11 | トゥヴァルディ セラピューティクス，インク． | Ｓｔａｔ３阻害剤 |
| US11026905B2 (en) * | 2018-04-19 | 2021-06-08 | Tvardi Therapeutics, Inc. | STAT3 inhibitors |
| JP2023520273A (ja) * | 2020-01-24 | 2023-05-17 | トゥヴァルディ セラピューティクス，インク． | 治療化合物、製剤、およびその使用 |
-
2019
- 2019-04-18 JP JP2020558021A patent/JP7411315B2/ja active Active
- 2019-04-18 PL PL19788688T patent/PL3773537T3/pl unknown
- 2019-04-18 MX MX2020011065A patent/MX2020011065A/es unknown
- 2019-04-18 BR BR112020021329-2A patent/BR112020021329A2/pt unknown
- 2019-04-18 PT PT197886880T patent/PT3773537T/pt unknown
- 2019-04-18 WO PCT/US2019/028135 patent/WO2019204614A1/en not_active Ceased
- 2019-04-18 ES ES19788688T patent/ES2911428T3/es active Active
- 2019-04-18 US US17/048,602 patent/US11826315B2/en active Active
- 2019-04-18 MY MYPI2020005483A patent/MY207195A/en unknown
- 2019-04-18 KR KR1020207033270A patent/KR102792113B1/ko active Active
- 2019-04-18 CN CN201980041259.1A patent/CN112367984B/zh active Active
- 2019-04-18 DK DK19788688.0T patent/DK3773537T3/da active
- 2019-04-18 HU HUE19788688A patent/HUE059318T2/hu unknown
- 2019-04-18 EP EP19788688.0A patent/EP3773537B1/en active Active
- 2019-04-18 EP EP22161820.0A patent/EP4070790A1/en active Pending
- 2019-04-18 AU AU2019255755A patent/AU2019255755B2/en active Active
- 2019-04-18 SG SG11202010347XA patent/SG11202010347XA/en unknown
-
2020
- 2020-10-18 IL IL278112A patent/IL278112B2/en unknown
- 2020-10-19 PH PH12020551728A patent/PH12020551728A1/en unknown
-
2023
- 2023-10-05 US US18/481,522 patent/US20240058284A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN112367984A (zh) | 2021-02-12 |
| ES2911428T3 (es) | 2022-05-19 |
| MY207195A (en) | 2025-02-05 |
| KR102792113B1 (ko) | 2025-04-04 |
| KR20210011925A (ko) | 2021-02-02 |
| JP7411315B2 (ja) | 2024-01-11 |
| US20240058284A1 (en) | 2024-02-22 |
| US11826315B2 (en) | 2023-11-28 |
| AU2019255755A1 (en) | 2020-12-03 |
| IL278112B2 (en) | 2023-07-01 |
| JP2021521243A (ja) | 2021-08-26 |
| EP3773537A1 (en) | 2021-02-17 |
| US20210114980A1 (en) | 2021-04-22 |
| IL278112B1 (en) | 2023-03-01 |
| PL3773537T3 (pl) | 2022-05-23 |
| PT3773537T (pt) | 2022-04-19 |
| AU2019255755B2 (en) | 2024-07-25 |
| MX2020011065A (es) | 2021-01-20 |
| EP4070790A1 (en) | 2022-10-12 |
| SG11202010347XA (en) | 2020-11-27 |
| HUE059318T2 (hu) | 2022-11-28 |
| CA3097403A1 (en) | 2019-10-24 |
| PH12020551728A1 (en) | 2021-06-14 |
| IL278112A (https=) | 2020-12-31 |
| EP3773537B1 (en) | 2022-03-23 |
| CN112367984B (zh) | 2024-05-10 |
| EP3773537A4 (en) | 2021-05-26 |
| DK3773537T3 (en) | 2022-04-25 |
| WO2019204614A1 (en) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020021329A2 (pt) | inibidores de stat3 | |
| US11026905B2 (en) | STAT3 inhibitors | |
| CN114174281A (zh) | 细胞周期蛋白依赖性激酶7(cdk7)的降解剂及其用途 | |
| WO2019204427A1 (en) | Methods for measuring and stabilizing stat3 inhibitors | |
| JP2023520595A (ja) | ピラゾロピリダジノン化合物、その医薬組成物及びその用途 | |
| WO2022206705A1 (zh) | 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途 | |
| WO2022005961A1 (en) | Prpk inhibitors | |
| KR101941794B1 (ko) | 아미노설포닐계 화합물, 이의 제조 방법 및 용도 | |
| CA3097403C (en) | Stat3 inhibitors | |
| JP2018522899A (ja) | ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法 | |
| HK40073672A (en) | Stat3 inhibitors | |
| CN108137614B (zh) | 一种稠合嘧啶化合物及包含该化合物的组合物及其用途 | |
| EA043779B1 (ru) | Ингибиторы stat3 | |
| HK40038526B (en) | Stat3 inhibitors | |
| HK40038526A (en) | Stat3 inhibitors | |
| WO2019120198A1 (zh) | 一类喹啉衍生物 | |
| EP3740208B1 (en) | Compounds for treating rac-gtpase mediated disorder | |
| EA046399B1 (ru) | Усовершенствованные синтетические способы получения (2h-1,2,3-триазол-2-ил)фенильных соединений в качестве модуляторов рецепторов орексина | |
| JP2020186182A (ja) | 標的蛋白質分解誘導化合物 | |
| WO2019120200A1 (zh) | 一类喹啉衍生物及其用途 | |
| WO2019120199A1 (zh) | 一类喹啉衍生物及其生物活性 | |
| BR112020000564A2 (pt) | novos derivados de heteroarilamida como inibidores seletivos das histonas desacetilases 1 e/ou 2 (hdac1-2) | |
| BR112017026994B1 (pt) | Composto, e, composição farmacêutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |